(Q54015370)

23 May 2018

title

Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. (English)

1 reference

23 May 2018

main subject

heart failure

0 references

congestive heart failure

1 reference

C A Sueta

1

1 reference

23 May 2018

M Gheorghiade

2

1 reference

23 May 2018

K F Adams

3

1 reference

23 May 2018

R C Bourge

4

1 reference

23 May 2018

S Murali

5

1 reference

23 May 2018

B F Uretsky

6

1 reference

23 May 2018

M R Pritzker

7

1 reference

23 May 2018

M D McGoon

8

1 reference

23 May 2018

S M Butman

9

1 reference

23 May 2018

S H Grossman

10

1 reference

23 May 2018

language of work or name

English

0 references

publication date

1 January 1995

1 reference

23 May 2018

American Journal of Cardiology

published in

1 reference

23 May 2018

volume

75

1 reference

23 May 2018

issue

3

1 reference

23 May 2018

page(s)

34A-43A

1 reference

23 May 2018

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Relation of right ventricular ejection fraction to exercise capacity in chronic left ventricular failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Right ventricular ejection fraction: An indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Factors influencing the one-year mortality of dilated cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Hemodynamic responses to prostacyclin (PGI2) in the conscious sheep.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Prostaglandin modulation of early afterdepolarizations and ventricular tachyarrhythmias induced by cesium chloride combined with efferent cardiac sympathetic stimulation in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Prostacyclin therapy in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Prostacyclin I2 (PGI2) increases left ventricular ejection fraction (LVEF).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Combined intravenous pharmacotherapy in the treatment of patients with decompensated congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Drug-induced conditioning in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Outpatient dobutamine and dopamine infusions in the management of chronic heart failure: clinical experience in 21 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Note on the sampling error of the difference between correlated proportions or percentages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Contractile responses to prostacyclin (PGI2) of isolated human saphenous and rat venous tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Prostaglandin I2 (PGI2) enhances calcium current in guinea-pig ventricular heart cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Effect of a prostacyclin derivative (iloprost) on regional blood flow, sympathetic nerve activity, and baroreceptor reflex in the conscious rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

The neurohumoral and hemodynamic response to orthostatic tilt in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Mechanisms governing the postural response and baroreceptor abnormalities in chronic congestive heart failure: effects of acute and long-term converting-enzyme inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Effect of prostacyclin and prazosin in the treatment of congestive heart failure; With special reference on the sympathetic nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Interrelationship between prostaglandins and renin release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Evidence for a direct stimulatory effect of prostacyclin on renin release in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Physiologic role of coronary PGI2 and PGE2 in modulating coronary vascular response to sympathetic stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

Myocardial ischemia during intravenous prostacyclin administration: hemodynamic findings and precautionary measures

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980381-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(99)80381-6

1 reference

23 May 2018

1 reference

23 May 2018